StockWatch
·

Saatvik Green Energy Ltd Q2 FY27 Results

SAATVIKGLQ2 FY27 Results
Filing
Result:Poor· Market: Down#Margin squeeze#Cost led#One-off hit

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue902.6176.6%17.5%
Total Income927.8978.5%18.5%
Expenditure897.2575.1%30.6%
PBT28.01278.2%70.9%
Net Profit20.25277.5%75.7%
OPM4.62%2.00pp9.49pp
NPM2.18%1.15pp8.45pp
EPS1.64281.4%77.8%
View full financials

Industrials core profitability metric (adjusted PAT) fell ~73-76% YoY as cost of materials absorbed nearly all the 17.5% revenue gain, crushing OPM to 4.6% from 14.1% — the second straight quarter of steep YoY profit decline and a miss-in-progress versus management's own FY27 margin guidance.

SAATVIKGL · Q2 FY-2027 · THE VERDICT

Revenue surges 17%, profit collapses 76%; cell ramp leaves margins in Q3

Saatvik delivered ₹902.6 Cr in Q2 revenue (+17.5% YoY), but net profit plunged 75.7% as margins compressed to 2.2% from guided 6-7%. Cell Phase 1 commissioned on schedule, but accretion benefit now deferred to Q3+, and FY27 ₹6,000 Cr revenue guidance is mathematically implausible.

11 Nov 2026 · 6 min read
Q2 Revenue

₹902.6 Cr

+17.5% YoY, +76.6% QoQ

Q2 PAT

₹20.2 Cr

-75.7% YoY despite revenue growth

PAT Margin

2.2%

vs 6-7% guidance; -350 to -450 bps miss

Capacity utilization

58.5%

Q2 modules; below required 70%+

On the surface, Saatvik's Q2 looks like a growth story — revenue climbed 17% year-on-year and surged 77% quarter-on-quarter. But the profit line tells a different story. Net profit fell 76% in a quarter of rising sales, a gap that reveals the real tension: margin compression has completely offset volume growth. This isn't about demand — it's about a company caught between two eras: the old module-led business running at fractional margins, and a cell-integrated future that hasn't yet kicked in.

Why profit fell despite rising revenue

The PAT margin fell to 2.2% in Q2 from 6-7% in the prior-year quarter and from management's FY27 guidance of 6-7%. EBITDA margin stands at 7.7% against a 12% target. The culprits, per the CFO: commodity pricing volatility and forex headwinds. Module segment remains 96% of sales, and at commodity-like DCR utility pricing (₹20/Wp), there's no margin cushion. Non-DCR orders fetch ₹12-13/Wp — higher margin but lower volume. The integrated cell manufacturing benefit — central to management's pitch — is not yet flowing through. Cell Phase 1 (2.4 GW) is live and undergoing ALMM inspection, but accretion to margins is now expected only from Q3 onwards, not Q2.

Q2 FY27 Profitability Bridge, ₹ Cr & %
0336.97673.941,010.91902.6Q2 FY27 revenue696Q2 EBITDA7.7EBITDA margin20.2Q2 PAT
EBITDA margin 7.7% vs 12% guided; PAT margin collapsed to 2.2% from Q2 FY26 11%.
Management's claims vs. what holds up

Q2 execution caught up with order book demand

Overstated

Sales 640 MW in Q2; order book 6.68 GW = 10+ quarters of supply. Capacity utilization only 58.5% suggests customer delays or demand softness, not catch-up.

Cell manufacturing ramp will drive 12% EBITDA margins in FY27

Contradicted

Q2 EBITDA margin 7.7%; PAT margin 2.2% vs 6-7% guided. Cell Phase 1 commissioned but accretion deferred to Q3+. ALMM inspection pending — no benefit in Q2.

FY27 ₹6,000 Cr revenue target remains on track

Contradicted

H1 FY27 delivered ₹1,413.6 Cr (23.6% of annual target). H2 would need ₹4,586.4 Cr — a 3.24x acceleration from H1 run-rate. At current 640 MW/qtr sales, mathematically implausible.

Odisha Phase 1 (1.3 GW modules) operational mid-November 2026

Supported

Phase 1 modules commissioned November 2, 2026. Production ramp to full capacity targeted December. Cell 2.4 GW ALMM inspection within 2-3 weeks post-Diwali.

What changed on this call

Phase 1 infrastructure is now live. The Odisha plant's 1.3 GW module capacity went operational in early November; cell and module manufacturing at the same location are expected to integrate by December. This is material — it marks the inflection from module-only to integrated manufacturing. But the margin accretion is now a Q3+ event. Management had previously signalled cell ramp benefits flowing through in Q2. That didn't happen. The ALMM (Approved List Methodology) inspection for the 2.4 GW cell line is now the gatekeeping event, scheduled within 2-3 weeks post-Diwali. If inspection passes on schedule, margin contribution begins in Q3 (partial) and Q4 (full), per management. If delayed, the timeline extends further. Capacity utilization sits at 58.5% — below the 70%+ required to hit FY27 guidance. This signals either customer delays (orders are queued at 6.68 GW but not yet converting to shipments at expected velocity) or softer demand than the headline order book suggests. Management framed Q2 as a 'realignment year' due to ALMM transition but offered no revised targets.

The bull-bear ledger
  • Strong 6.68 GW order book provides 10+ quarters of revenue visibility

  • Phase 1 Odisha plant commissioned on schedule; integration path clear

  • Long-term integrated manufacturing strategy (ingot → wafer → cell → module) is sound and capital-backed

  • PAT margin collapsed 75.7% YoY despite revenue growth; FY27 guidance credibility now in doubt

  • Capacity utilization 58.5% signals demand may be softer than order book suggests

  • ALMM inspection risk: if cell inspection is delayed, margin accretion pushed to Q4 or beyond

  • Module pricing power remains weak; utility segment (52% of revenue) locked in commodity-like DCR margins

Risks, ranked by how much they should concern a holder

FY27 revenue guidance is mathematically implausible

High

If target is revised downward (from ₹6,000 Cr to ~₹4,200 Cr implied by H1 + modest H2 acceleration), management credibility erodes. Multiple compression risk.

ALMM cell inspection timing slips beyond 2-3 weeks

High

Margin accretion from cell ramp is the story management sold. If inspection delays, margins stay compressed in Q3, pushing recovery to Q4 or FY28. Stock vulnerable to each delay news.

Capacity utilization stays <70% through Q3

High

Current 58.5% utilization flags demand softness. If not fixed, integrated model economics don't work. Module pricing spiral risk in a supply-surplus market.

China export controls (Section 232 / Dec 4, 2026) disrupt long-term wafer supply contracts

Medium

Saatvik sources tier-1 China wafer; Phase 3 ingot/wafer (FY29) is not on stream yet. Tech/supply constraints could force price hikes or delays.

Commodity pricing volatility continues; no pricing power with utility customers

Medium

CFO cited forex and commodity swings for margin miss. With 52% utility revenue locked at DCR rates, margin sensitivity to raw materials is high. Hedge or diversify needed.

How the street is positioned

Post-result price action — no pop, persistent weakness. The stock opened the result period at ₹359.1 on 2026-11-11 (report date), below all major moving averages (SMA20 ₹366.49, SMA50 ₹395.04, SMA200 ₹419.37). RSI sits at 41.8 (neutral momentum). The lack of a post-result rally is telling — the market read the margin miss and the guidance gap the same way an analyst does. The stock remains down 36.67% from its all-time high of ₹567, and off the 52-week low of ₹328 by just 9.48%. The momentum is bearish, not because the stock is cheap, but because execution is now in doubt. Valuation drawdown context. At ₹359.1, Saatvik sits at a 35% discount to its ATH on the back of three quarters of strategic execution (Phase 1 commissioned, cell ramp underway) that has *not yet paid off*. A drawdown this steep usually signals either a repricing of long-term value (justified if the integrated thesis stalls) or an opportunity (if ALMM clears and utilization rebounds). The market has chosen the former — it's betting the thesis doesn't work at these margins and utilization levels. That's a risk you can't ignore. Foreign investors are exiting; domestic holding steady. Foreign institutional ownership has collapsed from 0.46% in Q2 FY26 to just 0.19% as of Q1 FY27 — a 60% trim in FII exposure. Domestic institutional ownership remains stable at 10.97%, and promoters stay locked at 75.99% (unchanged all year). The FII exit is significant: it signals that global capital is uncomfortable with execution risk and guidance credibility at current levels. Domestic institutions have not followed — yet. That's a divergence worth watching.

What to watch next
  • 1 · ALMM cell inspection outcome (within 2-3 weeks post-Diwali)

    This is the gate. If inspection passes and production ramp proceeds on schedule, Q3 will show the first margin contribution from cell manufacturing. Stock could re-rate 10-15% on clear. If delayed, margin accretion pushes to Q4 or FY28 — near-term pain continues.

  • 2 · Q3 FY27 capacity utilization (December 2026 onwards)

    Management targets 70%+ utilization to hit margin guidance. Watch whether Phase 1 ramp accelerates order conversion or whether customer delays persist. Utilization >70% + cell integration = confidence recovery. <65% = demand problem.

  • 3 · FY27 revenue guidance revision or restatement

    If management quietly revises FY27 from ₹6,000 Cr downward (to ₹4,200-4,500 Cr implied), credibility gap widens — stock could lose another 10-15%. If they reiterate, watch actual H2 sales velocity closely. If it accelerates 2x from H1, thesis may still work. If it stays flat, guidance is toast and management loses analyst support.

Saatvik is not a broken story — Phase 1 is live, order book is real, and the integrated manufacturing thesis is sound. But execution has lagged capital deployment, and FY27 guidance is implausible. This quarter is not a 'hold through; it's a 'pause and watch for catalysts.' PAT margin of 2.2% vs 6-7% guidance is a massive miss; it won't be solved by Q3 unless cell accretion is immediate and utilization jumps. The stock's 35% drawdown from ATH reflects that doubt. Wait for ALMM clearance and utilization inflection before adding. The number to track from here is Q3 capacity utilization — if it's still below 65%, the demand problem is real and the integrated thesis hits a wall. If it's >70%, the risk reward turns.

Informational and educational content only. Not investment advice.